Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is an experimental small molecule with the chemical formula C24H30FN7O and a molecular weight of approximately 451.54 g/mol[1][2]. It belongs to the class of organic compounds known as benzamides[2]. There are no approved indications, clinical trials, or patents associated with this molecule, and it is not currently marketed as a pharmaceutical product[2]. Its mechanism of action, biological targets, and therapeutic potential have not been described in publicly available sources. The compound has been cataloged in several chemical databases (PubChem CID: 16113377; DrugBank ID: DB07936; ChEMBL ID: CHEMBL460102)[1][6].
- Other names
- N-(4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]carbonyl}phenyl)-5-Fluoro-4-[2-Methyl-1-(1-Methylethyl)-1h-Imidazol-5-Yl]pyrimidin-2-AmineN-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yI)carbonyl}phenyl}-5-fluoro - 4 - [2-methyl - 1 -(propan - 2 - yl) - 1H-imidazol - 5 - yl]pyrimidin – 2 – amine
02
Targets
GRPR (Gastrin-releasing peptide receptor)NMBR (Neuromedin B receptor)
Beyond the preview
Go deeper on N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine.